AMERICA

Novavax Begins COVID-19 Vaccine Trials After $388 Million Funding From Bill Gates-Backed Organization

Novavax Begins COVID-19 Vaccine Trials After $388 Million Funding From Bill Gates-Backed Organization
Novavax, a Rockville, Maryland company, Md., on April 28, 2009. Paul J. Richards/AFP via Getty Images
Isabel van Brugen
|Updated:

Novavax, a U.S. biotechnology company that received funding from a Bill Gates-backed organization, has started phase 1 of its clinical trials for a CCP (Chinese Communist Party) virus vaccine.

The Maryland-based company said on Monday it is beginning human trials of the vaccine in Australia, and expects preliminary immunogenicity and safety results in July.

Isabel van Brugen
Isabel van Brugen
Reporter
Isabel van Brugen is an award-winning journalist. She holds a master's in newspaper journalism from City, University of London.
twitter
Related Topics